Trust me, nothing would please me more than for this delay to be caused by a DSMC or FDA process that leads to favorable outcome.

However, don't exclude the possibility that the call is maybe being delayed in order to incrementally advance a discussion with an ex-US regulatory agency -- not so an ex-US approval can be announced -- but maybe just to harvest a generally positive development that can help offset shareholder disappointment with possibly needing to complete the trial.